This is a routine executive compensation vesting event with no trading signal. Monitor for any future open-market sales by the CFO, which would be reported via Form 4 or Form 6-K.
AZN drugs
AZN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 19 $164.95entry
- T+1 · 3mo ago −0.28%α +0.56% · $164.49
- T+5 · 3mo ago +0.80%α +1.19% · $166.27
- T+20 · 2mo ago −1.88%α −0.36% · $161.85
- T+60 · 4d ago +12.45%α +13.27% · $185.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
AstraZeneca filed a Form 6-K reporting the vesting of a long-term performance share award to CFO Aradhana Sarin. The award, granted in 2021 under the AstraZeneca Performance Share Plan, vested on 17 August 2026 after a three-year performance period and a two-year holding period. This is a routine administrative disclosure regarding executive compensation and has no material impact on the company's financials or operations.
Key Facts
- CFO Aradhana Sarin received 11,133 ordinary shares upon vesting of a 2021 performance share award.
- The shares were acquired for nil consideration under the AstraZeneca Performance Share Plan.
- The fair market value at vest was £114.60 per share.
- Shares were withheld to satisfy tax obligations; the net change in beneficial interest is not disclosed.
- This is the first PSP award to vest for Dr. Sarin since her appointment as CFO in 2021.
Financial Impact
No material financial impact. The vesting of 11,133 shares represents approximately 0.0007% of outstanding shares.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-007742 |
| Document: 0001654954-26-007742-index-headers.html | 0001654954-26-007742 |
| Document: 0001654954-26-007742-index.html | 0001654954-26-007742 |
| Document: 0001654954-26-007742.txt | 0001654954-26-007742 |
Track record
77 reports on AZN
19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers